My Insights
Do you wish there was a way to help patients see their ongoing device management trends and get helpful pointers delivered straight to them automatically? There is! Introducing My Insights; cutting edge tailored Medtronic support!
My Insights is a new personal report exclusively for patients who use the MiniMedTM 770G system; it is an optional benefit and is complimentary for patients. Tailored reports include the patient’s latest Time in Range (TIR) trends, personalized opportunities and insights based on their device data. Unique support videos and resources and rewarding achievement badges that mark patient progress along the way are offered as well. Additionally, helpful tips can aid patients in improving their experience with their MiniMedTM 770G system. In brief, My Insights helps identify and deliver educational content that is most relevant to the patient based on what they are experiencing.
My Insights reports are sent directly to the patient’s email every month. The report data is presented in a fresh, concise, uplifting, and motivating way; it’s personalized, too. Patients can consent to participate in the My Insights program by logging into their diabetes.shop account, scrolling to “Communication Preferences,” and then selecting “Provide Consent” underneath the “Personalized Insights” communications category. Program communication emails are sent directly to patients and will come from CustomerExperience@Medtronic.com. So long as the patient’s continuous glucose monitor data is uploading to CareLinkTM Personal Software through the MiniMedTM Mobile App or a computer via the blue adaptor, the first My Insights report will arrive in 2 to 6 weeks. This will continue in a cadence of 1 month thereafter as long as sufficient data flow is generated from the patient’s pump system use.
As one lifelong pump patient and recent My Insights recipient said, “I did not expect the emotion I got from the encouragement. I didn’t realize that was something I was missing and really appreciated the support.”
For more information, visit the Medtronic Diabetes website or contact your local representative.
Important Safety Information: MiniMed™ 770G System with SmartGuard™ Technology
The MiniMed™ 770G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons two years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 770G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM) sensor glucose (SG) values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Medtronic MiniMed™ 770G system consists of the following devices: MiniMed™ 770G insulin pump, the Guardian™ Link (3) transmitter, the Guardian™ Sensor (3), one-press serter, the Accu-Chek® Guide Link blood glucose meter, and the Accu-Chek® Guide test strips. The system requires a prescription.
The Guardian™ Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ Sensor (3).
All therapy adjustments should be based on measurements obtained using the Accu-Chek® Guide Link blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek® Guide Link blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.
WARNING: Do not use the SmartGuard™ Auto Mode for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in SmartGuard™ Auto Mode.
WARNING: Do not use the MiniMed™ 770G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 770G system.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 770G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-770g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library